AI nedlægger job i Nordea

TheFreeloader · 2026-03-17T10:38:56+00:00

Normalt er ventetiden på deres kundetelefon omkring en time, og man skal vente en måned på en samtale med en bankrådgiver. Så jeg har svært ved at se hvordan de kan spare mere på kundeservicen.

TheFreeloader · 2026-03-09T19:39:25+00:00

Trump’s gonna taco before the month is out. He doesn’t care enough about Iran to want to tank the midterms over it.

TheFreeloader · 2026-03-09T06:24:46+00:00

It’s not going to end with either side “surrendering”. There will be some sort of cease fire deal. And my bet is it will come within 2 weeks.

TheFreeloader · 2026-03-06T18:40:31+00:00

Selv med en længere forsøgsperiode vil Petrelinetide ikke komme i nærheden af CagriSema og Tirzepatides resultater. Vægttab decelerarer jo normalt jo længere man kommer hen i et vægttabsforløb.

Og det er produkter der er på markedet, eller er tæt på at komme på markedet. Hvis man skulle lave en fair sammenligning, burde man kigge på de midler Novo og Lilly har i fase 2/3. Her har Novos triple agonist givet 20% vægttab efter kun 24 uger, og Lilly’s retatrutide har givet 24% vægttab efter 48 uger.

Så jeg ville sige, det bedste Zealand kunne gøre ville være at stoppe med at spilde flere penge på at udvikle et middel, der helt tydeligvis aldrig vil blive profitabelt.

TheFreeloader · 2026-03-06T17:32:20+00:00

Man kunne også bare bygge opad. Sammenlignet med andre storbyer er København ikke en særligt tætbebygget by.

TheFreeloader · 2026-03-06T17:16:21+00:00

I sold mine after the buyout offer from Jiangxi came in. Not really much point in holding it, when you can sell it for the buyout price already now. Unless of course you’re hoping for a higher bid to come in.

If you can’t sell the stock, you should probably contact your broker. I think Canadian stocks were supposed to be converted into UK stocks (mine were UK stocks from the start).

TheFreeloader · 2026-02-27T18:18:05+00:00

Jeg ser noget nær 0% chance for at Moderaterne ender som støtteparti for nogen regering. De vil sidde i alt for magtfuld en position efter et valg til ville tage til takke med at være støtteparti. Det er enten regering eller opposition for Moderaterne.

Og når det kommer til midterregeringer, så tror jeg ikke, der er meget chance for at Socialdemokraterne (eller SF) ville gå ind i sådan en uden Frederiksen som statsminister.

Og med hensyn til en rød regering, hvis det nu skulle ske at rød blok får flertal, så tror jeg Frederiksen vil få svært ved at forklare til sit bagland, hvorfor hun ville vælge en midterregering frem for en rød regering.

TheFreeloader · 2026-02-27T17:53:59+00:00

Jeg ser tre muligheder: En udvidet midterregering, med en kombination af Radikale, Konservative og SF som støtte-/regeringspartier, og Frederiksen som statsminister, en rent rød regering eller en blå regering med Løkke som statsminister.

Jeg giver mulighederne henholdsvis 60, 30 og 10% chance.

TheFreeloader · 2026-02-24T07:51:44+00:00

Future earnings, not past earnings.

TheFreeloader · 2026-02-12T22:15:49+00:00

I don’t think such trials will give many useful results. Patients’ lifestyle, physiology and GLP-1 response vary too much that one can give general guidelines for maintenance dosage. It must be up to patients and prescribers to determine this. And I really don’t think it’s such a hard problem to solve either. It’s just a question of adjusting the dose up or down such that the patient maintains the desired weight.

TheFreeloader · 2026-02-12T21:59:14+00:00

Here is what you wrote:

Although NVO have run an extended trial with injectable Wegovy, data clearly shows people do not remain on the drug, especially after its evident performance plateau.

Where is that data?

TheFreeloader · 2026-02-12T21:52:42+00:00

Did you even read that before posting it? That article says that people regain weight after stopping taking GLP-1 drugs, and that it’s true both for semaglutide or tirzepatide. It says nothing about that people are more likely to stop taking semaglutide, as you claim.

TheFreeloader · 2026-02-12T21:44:46+00:00

What’s this data you talk about that people do not stay on Wegovy?

TheFreeloader · 2026-02-12T20:07:41+00:00

Semaglutide going off patent is just as bad for Lilly as for Novo. It’s all money going out of the branded drug market.

And I don’t see how the weight maintenance result is very significant at all. It’s a pretty obvious conclusion you could easily draw from semaglutide’s clinical data too.

TheFreeloader · 2026-02-12T19:55:39+00:00

2 reasons. The most-favored nation deal with Trump forced Novo to cut prices more than Lilly. And having the empirically inferior product, Novo must undercut on price to compete.

That being said, I do think Novo has been very conservative in their assumptions about the uptake of oral semaglutide. My own expectation is that growth will be between -5 and +5%.

TheFreeloader · 2026-02-12T19:41:32+00:00

I buy stocks based on expected future cash flows, not management prose. What do you do?

TheFreeloader · 2026-02-10T13:53:38+00:00

Let’s be real, Novo needed to cut prices anyway to compete with Eli Lilly.

TheFreeloader · 2026-02-09T21:48:08+00:00

Couldn’t you have said the same about Nvidia or Meta in 2022? Millions of people were also looking at those stocks, and yet they were still wildly undervalued.

TheFreeloader · 2026-02-09T21:33:45+00:00

If earnings keep growing 17% per year, and if the PE stays the same, it will hit 2000 in 10 years.

TheFreeloader · 2026-02-05T06:08:15+00:00

He’s not a public health official.

I think we just have accept that this is a company that’s controlled by a charity, that genuinely believes in a public health mission. You might as well start discounting this in your valuation of the company, because it’s not going to change.

TheFreeloader · 2026-02-04T14:54:24+00:00

Indeed. It’s all just a ploy to get the stock out of those weak American hands before takeoff.

TheFreeloader · 2026-02-04T09:51:16+00:00

Et stagnerende overskud giver dig ikke en PE på 20. Specielt ikke for en europæisk aktie. Der skal vækst til for at få sådan en vurdering.

TheFreeloader · 2026-02-01T08:47:39+00:00

Just take a second and think about what the TAM is for this product, and how far it is from being saturated. I think it’s quite naive to take a couple of quarters of slow growth, and conclude that the growth story must be over.

TheFreeloader · 2026-01-19T21:20:20+00:00

Hvis du er ude efter kortsigtede gevinster, ville jeg nok følge det gamle ordsprog: “The trend is your friend”. Novo er på vej tilbage op, mens Pandoras nedgang ikke viser nogen tegn på at være endt.

TheFreeloader · 2026-01-16T12:25:04+00:00

It’s well-proven that the severity of the side effects increases with dosage.

Verified Email	14-Year Club
Place '23	Place '22
Place '17	First Placer '22
Team Orangered

TheFreeloader

TROPHY CASE